Investors are pouring money into gene and cell therapy

Investors are pouring money into gene and cell therapy

QUARTERLY DATA REPORT FROM THE ALLIANCE FOR REGENERATIVE MEDICINE

You probably already knew that there's a ton of activity and investment in the cell and gene therapy space. But just how much? A new reporttakes a stab at quantifying the excitement.

The analysis comes from the Alliance for Regenerative Medicine, a trade group for companies working on gene and cell therapies and tissue-engineered products.

Among the findings:

• Companies in the space collectively raised more than $4.1 billion in the second quarter of this year, up 164 percent over the same period in 2017.
• More and more companies in the space are turning to the public markets. They collectively raised $913.4 million in IPOs so far this year, up from $254 million during all of last year. 
• Nearly 977 clinical trials testing such therapies are in progress across the globe; more than half of them are trying to treat cancer.

ARM_Q2_2018_Web